Biotech stocks rally on drug innovation and M&A
Moderna gave investors a scare as its stock plunged on Thursday. But it’s still one of the hottest…
Pfizer vs. Medtronic: Which Healthcare Turnaround is More Convincing?
Pfizer Inc. (NYSE:PFE) and Medtronic plc (NYSE:MDT) are both trying to prove that years of portfolio investment can…
AbbVie vs. Pfizer: Which Healthcare Stock Makes Your Portfolio Healthier in 2026?
Deciding between two pharmaceutical giants requires a close look at pipeline growth and patent longevity. For investors in…
Chinese biopharma stocks jump as U.S. plans to continue drug licensing deals
A young female worker in protective gear carefully carries a container filled with blister-packaged capsules, a crucial step…
Jim Cramer Picks J&J (JNJ) Over Eli Lilly (LLY) and Pfizer (PFE) Among These Healthcare Stocks
On September 3, a caller asked whether to rotate out of artificial intelligence stocks and add to Eli…
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
The pharmaceutical industry is shifting as legacy blockbusters lose patent protection. Investors must choose between AbbVie Inc (NYSE:ABBV)…
Pfizer’s Turnaround is Gaining Traction, but Can New Products Offset its Patent Cliff?
Pfizer Inc. (NYSE:PFE) is beginning to show signs of steadier growth following the sharp decline in its pandemic-related…
Here are the 2 big things we’re watching in the stock market in the week ahead
The jobs market steps into the spotlight this week, while second-quarter earnings season continues apace. Here’s a closer…
What to know about testosterone replacement therapy
US Secretary of Defense Pete Hegseth speaks during a press briefing at the Pentagon in Washington, DC, on…
Stocks making the biggest moves premarket: INTC, SPCX, MU, CCL
Check out the companies making the biggest moves in premarket trading: Intel — The semiconductor company soared nearly…
U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Approval expands HYMPAVZI use to now include people with hemophilia A or B ages 12 years and older…
Space race comes for pharma: Why drug development is heading to orbit
The highly anticipated SpaceX mega-IPO is part of a space frenzy that is moving beyond satellite connectivity, launch…